Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8638829 | 0.77 | ADRB2 (0.48) | HIF1AADRA2AADRA2CLMNAKDM4E | |
| SCHEMBL24008886 | 0.77 | ADRB2 (0.48) | HIF1AADRA2AADRA2CLMNAKDM4E | |
| SCHEMBL207149 | 0.74 | ACHE (0.39) | HIF1AADRA2AADRA2CLMNAKDM4E | |
| SCHEMBL22785846 | 0.74 | CYP3A4 (0.46) | TSHRCYP3A4HIF1AADRA2AADRA2C | |
| SCHEMBL30988812 | 0.74 | CYP3A4 (0.46) | TSHRCYP3A4HIF1AADRA2AADRA2C | |
| SCHEMBL28674297 | 0.74 | ABCB11 (0.44) | HIF1AADRA2AADRA2CLMNAKDM4E | |
| SCHEMBL29256523 | 0.74 | CYP3A4 (0.46) | TSHRCYP3A4HIF1AADRA2AADRA2C | |
| SCHEMBL14038059 | 0.73 | TSHR (0.47) | TSHRCYP3A4HIF1AADRA2AADRA2C | |
| SCHEMBL7589227 | 0.73 | CYP3A4 (0.38) | TSHRCYP3A4ADRA2AADRA2CLMNA | |
| SCHEMBL24015471 | 0.71 | ADRB2 (0.30) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3906969-A1 | ANTIHYPERTENSIVE POLYOL COMPOUND AND DERIVATIVE THEREOF | East China University of Science and Technology (CN) | 2021-11-10 | — | — | EP | disclosed |
| WO-2020249117-A1 | ANTIHYPERTENSIVE POLYOL COMPOUND AND DERIVATIVE THEREOF | 华东理工大学 | 2020-12-17 | — | — | WO | disclosed |
| US-8088941-B2 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2012-01-03 | — | — | US | disclosed |
| US-20080312188-A1 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2008-12-18 | — | — | US | disclosed |
| US-7378432-B2 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2008-05-27 | — | — | US | disclosed |
| US-20060069066-A1 | 3-(4-(3-guanidinophenyl)-1,2,3-triazol-1-yl)benzyl phosphoric acid hydrochloride; obesity, non-insulin dependent diabetes mellitus, insulin-dependent condition, affective disorder, neurodegenerative diseases, psychotic disease; compounds having hydrophobic moiety to a terminus of a peptide GSK-3 | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069066-A1 | 3-(4-(3-guanidinophenyl)-1,2,3-triazol-1-yl)benzyl phosphoric acid hydrochloride; obesity, non-insulin dependent diabetes mellitus, insulin-dependent condition, affective disorder, neurodegenerative diseases, psychotic disease; compounds having hydrophobic moiety to a terminus of a peptide GSK-3 | GSK3A, GSK3B, PYGB | TSHR 1919/4885CYP3A4 4258/4885HIF1A 4445/4885 |
| US-20080312188-A1 | Glycogen synthase kinase-3 inhibitors | GSK3B, GSK3A, GSKIP | TSHR 4565/4885CYP3A4 2185/4885HIF1A 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.